NeuroSense (NRSN) 6-K adds proxy materials to F-3 and S-8

Rhea-AI Filing Summary

NeuroSense Therapeutics Ltd. (NRSN) submitted a Form 6-K as a foreign private issuer, mainly to furnish materials for an upcoming shareholder vote. The filing attaches a Notice and Proxy Statement for a special meeting of shareholders scheduled for December 30, 2025, along with a proxy card that shareholders can use to cast their votes.

The company also states that this Form 6-K is incorporated by reference into its existing shelf and employee benefit registration statements on Form S-8 and Form F-3. This linkage means the information in this report is now legally part of those registration statements, which can be relevant for future securities offerings and equity compensation plans.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

_______________

FORM 6-K

_______________

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

For the month of November 2025

Commission File Number: 001-41084

_______________

NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)

_______________

NeuroSense Therapeutics Ltd.
11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9- 7996183
(Address of principal executive offices)

_______________

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒            Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Attached hereto and incorporated herein by reference are the following exhibits:

Exhibit 99.1		Notice and Proxy Statement for the Special Meeting of Shareholders of the registrant scheduled for December 30, 2025
Exhibit 99.2		Proxy Card

This Report on Form 6-K is hereby incorporated by reference into registrant’s Registration Statements on Form S-8 (File No. 333-262480 and 333-289658) and Form F-3 (File No. 333-269306, 333-260338, 333-283656, 333-284051 and 333-291122), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		NeuroSense Therapeutics Ltd.
Dated: November 21, 2025		By:		/s/ Alon Ben-Noon
				Alon Ben-Noon
				Chief Executive Officer

2

FAQ

What did NeuroSense Therapeutics (NRSN) file on this Form 6-K?

NeuroSense Therapeutics filed a Form 6-K as a foreign private issuer to provide a Notice and Proxy Statement for a special meeting of shareholders and an accompanying proxy card.

When is the NeuroSense Therapeutics (NRSN) special shareholder meeting scheduled?

The special meeting of shareholders of NeuroSense Therapeutics Ltd. is scheduled for December 30, 2025, as stated in the Notice and Proxy Statement referenced in the filing.

What exhibits are included with NeuroSense Therapeutics' November 2025 Form 6-K?

The filing includes two main exhibits: Exhibit 99.1, the Notice and Proxy Statement for the special meeting of shareholders, and Exhibit 99.2, the Proxy Card.

How does this Form 6-K relate to NeuroSense Therapeutics' existing registration statements?

The company states that this Form 6-K is incorporated by reference into its Registration Statements on Form S-8 (File Nos. 333-262480 and 333-289658) and Form F-3 (File Nos. 333-269306, 333-260338, 333-283656, 333-284051 and 333-291122).

Who signed the NeuroSense Therapeutics (NRSN) Form 6-K?

The Form 6-K was signed on behalf of NeuroSense Therapeutics Ltd. by Alon Ben-Noon, who is identified as the company’s Chief Executive Officer.

Does the NeuroSense Therapeutics Form 6-K include financial results or earnings data?

No, this Form 6-K focuses on proxy materials for a special shareholder meeting and the incorporation of this report into existing registration statements, rather than financial or earnings data.